Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Patients who have been treated in study protocol BAP089 may have responded to treatment, and
subsequently relapsed to >75% of the baseline disease severity, will be investigated for
response to further treatment with alitretinoin. Also, patients who have responded with mild
or moderate disease will be investigated for additional treatment effect after prolongated
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Patients with severe chronic hand dermatitis, that has not responded to topical treatment,
including topical steroids and the avoidance of aggravating factors, will be treated with the
oral medication alitretinoin. The study aims to investigate the safety and efficacy of the
medication when given over a period of 6 months.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.